Medicinal Materials Research Center
Medicinal Materials Research Center

Medicinal Materials Research Center

The Medicinal Materials Research Center develops novel pharmaceutical materials for the treatment of incurable diseases. Our research interests are i) development of cancer immunotherapeutics, ii) development of tumor immune microenvironment reprogramming technology, and iii) development of precision cancer immunotherapy technology. Simultaneously, we strive to realize precision medicine (prevention, diagnosis, and treatment) for the treatment of incurable diseases through the development of patient-specific treatment technology based on ‘theragnosis’ technology and immune fusion technology.

Sun Hwa Kim
Head, Medicinal Materials Research Center

Scientific Highlight
  • Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity (Biomaterials, 2021)
  • The safe and effective intraperitoneal chemotherapy with cathepsin B-specific doxorubicin prodrug nanoparticles in ovarian cancer with peritoneal carcinomatosis (Biomaterials, 2021)
  • Visible-Light-Triggered Prodrug Nanoparticles Combine Chemotherapy and Photodynamic Therapy to Potentiate Checkpoint Blockade Cancer Immunotherapy (ACS Nano, 2021)
  • Combination of cancer-specific prodrug nanoparticle with Bcl-2 inhibitor to overcome acquired drug resistance (Journal of Controlled Release, 2021)
  • Systemic delivery of CRISPR/Cas9 to hepatic tumors for cancer treatment using altered tropism of lentiviral vector (Biomaterials, 2021)
  • A novel therapeutic modality using CRISPR-engineered dendritic cells to treat allergies (Biomaterials, 2021)
  • A Trojan-Horse Strategy by In Situ Piggybacking onto Endogenous Albumin for Tumor-Specific Neutralization of Oncogenic MicroRNA (ACS Nano, 2021)
  • In vivo tracking of bioorthogonally labeled T-cells for predicting therapeutic efficacy of adoptive T-cell therapy (Journal of Controlled Release, 2021)
  • Xenogenization of tumor cells by fusogenic exosomes in tumor microenvironment ignites and propagates antitumor immunity (Science Advances, 2020)
Research Scople

Tumor microenvironment and immune cell reprogramming

  • Anticancer immune response activation based on tumor microenvironment remodelling
  • Immune cell activation and reprogramming technology
  • Immune checkpoint regulation technology
  • Tumor-targeted cell therapy

Development of anti-cancer vaccine platform and immunotherapeutics

  • Development of cancer vaccine nanoplatforms
  • Development of cancer vaccine delivery technology
  • Discovering novel immunotherapeutics and immune modulators

Development of complex formulation of immunotherapeutics and precision anticancer immunotherapy technology

  • Development of complex formulation of immunotherapeutics
  • Development of combination cancer immunotherapy technology
PIs & News
44.김선화_
KIM SUN HWA
Head
37.권익찬_
Kwon, Ick Chan
Principal Researcher
39.김은경_
Kim, Eunice Eun-Kyeong
Principal Researcher
36.김광명_
Kim, Kwangmeyung
Principal Researcher
yys
YANG YOO SOO
Principal Researcher
42.안형준_
Ahn Hyung Jun
Principal Researcher
yhy
YOUN HONG YEOL
Senior Researcher
47.류주희_
Ryu Ju Hee
Principal Researcher
53.장미희_
MIHUE JANG
Principal Researcher
photo_선인철
Sun, In-Cheol
Senior Researcher
image08
Wooyoung Hur
Senior Researcher
image05
Taekhoon Kim
Senior Researcher